{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:57:15Z","timestamp":1775786235248,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1245\/s10434-020-09152-8","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T16:03:11Z","timestamp":1600963391000},"page":"2182-2190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer"],"prefix":"10.1245","volume":"28","author":[{"given":"Monica M.","family":"Grova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula D.","family":"Strassle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma E.","family":"Navajas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristalyn K.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Ollila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie M.","family":"Downs-Canner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-0178","authenticated-orcid":false,"given":"Philip M.","family":"Spanheimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"issue":"3","key":"9152_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/annonc\/mdq345","volume":"22","author":"S Dawood","year":"2011","unstructured":"Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22(3):515\u201323.","journal-title":"Ann Oncol."},{"issue":"13","key":"9152_CR2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/jnci\/dji172","volume":"97","author":"KW Hance","year":"2005","unstructured":"Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97(13):966\u201375.","journal-title":"J Natl Cancer Inst."},{"issue":"30","key":"9152_CR3","doi-asserted-by":"publisher","first-page":"49370","DOI":"10.18632\/oncotarget.17217","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Xia Y, Wu Q, et al. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: a population-based study from the SEER program. Oncotarget. 2017;8(30):49370\u20139.","journal-title":"Oncotarget."},{"issue":"2","key":"9152_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1634\/theoncologist.8-2-141","volume":"8","author":"M Cristofanilli","year":"2003","unstructured":"Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003;8(2):141\u20138.","journal-title":"Oncologist."},{"issue":"6","key":"9152_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3322\/caac.20082","volume":"60","author":"FM Robertson","year":"2010","unstructured":"Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60(6):351\u201375.","journal-title":"CA Cancer J Clin."},{"issue":"9","key":"9152_CR6","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/cncr.25682","volume":"117","author":"S Dawood","year":"2011","unstructured":"Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011;117(9):1819\u201326.","journal-title":"Cancer."},{"issue":"4","key":"9152_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/jso.2930180405","volume":"18","author":"F Bozzetti","year":"1981","unstructured":"Bozzetti F, Saccozzi R, De Lena M, Salvadori B. Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol. 1981;18(4):355\u201361.","journal-title":"J Surg Oncol."},{"issue":"10","key":"9152_CR8","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1245\/s10434-017-5952-x","volume":"24","author":"KJ Rosso","year":"2017","unstructured":"Rosso KJ, Tadros AB, Weiss A, et al. Improved locoregional control in a contemporary cohort of nonmetastatic inflammatory breast cancer patients undergoing surgery. Ann Surg Oncol. 2017;24(10):2981\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"15","key":"9152_CR9","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.7150\/jca.31176","volume":"10","author":"GR Devi","year":"2019","unstructured":"Devi GR, Hough H, Barrett N, et al. Perspectives on inflammatory breast cancer (IBC) research, clinical management and community engagement from the Duke IBC Consortium. J Cancer. 2019;10(15):3344\u201351.","journal-title":"J Cancer."},{"issue":"9","key":"9152_CR10","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1245\/s10434-017-5903-6","volume":"24","author":"F Nakhlis","year":"2017","unstructured":"Nakhlis F, Regan MM, Warren LE, et al. The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer. Ann Surg Oncol. 2017;24(9):2563\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"9152_CR11","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1245\/s10434-019-07597-0","volume":"26","author":"FO Imeokparia","year":"2019","unstructured":"Imeokparia FO, Hughes TM, Dossett LA, Jeruss JS, Chang AE, Sabel MS. Axillary pathologic complete response in inflammatory breast cancer patients: implications for SLNB? Ann Surg Oncol. 2019;26(10):3374\u20139.","journal-title":"Ann Surg Oncol."},{"key":"9152_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hernan","year":"2016","unstructured":"Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70\u20135.","journal-title":"J Clin Epidemiol."},{"key":"9152_CR13","unstructured":"Inflammatory Breast Cancer. NCCN Guideline Version 3.2020 Web site. Accessed 29 March 2020."},{"issue":"1","key":"9152_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10549-020-05529-1","volume":"180","author":"OM Fayanju","year":"2020","unstructured":"Fayanju OM, Ren Y, Greenup RA, et al. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Res Treat. 2020;180(1):207\u201317.","journal-title":"Breast Cancer Res Treat."},{"issue":"7","key":"9152_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1245\/s10434-009-0452-2","volume":"16","author":"RJ Tsai","year":"2009","unstructured":"Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C. The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol. 2009;16(7):1959\u201372.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"9152_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s10549-011-1667-z","volume":"130","author":"RL Ahmed","year":"2011","unstructured":"Ahmed RL, Schmitz KH, Prizment AE, Folsom AR. Risk factors for lymphedema in breast cancer survivors, the Iowa Women\u2019s Health Study. Breast Cancer Res Treat. 2011;130(3):981\u201391.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"9152_CR17","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ijrobp.2013.11.232","volume":"88","author":"LE Warren","year":"2014","unstructured":"Warren LE, Miller CL, Horick N, et al. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys. 2014;88(3):565\u201371.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"9152_CR18","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.clbc.2017.06.014","volume":"18","author":"SM DeSnyder","year":"2018","unstructured":"DeSnyder SM, Mittendorf EA, Le-Petross C, et al. Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer. Clin Breast Cancer. 2018;18(1):e73\u20137.","journal-title":"Clin Breast Cancer."},{"issue":"3","key":"9152_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijsu.2009.04.012","volume":"7","author":"S Hidar","year":"2009","unstructured":"Hidar S, Bibi M, Gharbi O, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg. 2009;7(3):272\u20135.","journal-title":"Int J Surg."},{"issue":"10","key":"9152_CR20","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072\u20138.","journal-title":"J Clin Oncol."},{"issue":"22","key":"9152_CR21","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359.","journal-title":"N Engl J Med."},{"issue":"7","key":"9152_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09152-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09152-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09152-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T05:03:00Z","timestamp":1632459780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09152-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["9152"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09152-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}